How does ASTH's Q3 earnings trend compare to forecasts?

Astrana Health, Inc. (ASTH) experienced a slight discrepancy between its Q3 2024 earnings and revenue figures and market forecasts.

1. **Earnings Per Share (EPS)**:
- The company reported an EPS of $0.40 for Q3 2024.
- Analysts had forecasted an EPS of $0.38 for the quarter.
- Thus, ASTH surpassed EPS expectations by $0.02.
2. **Revenue**:
- Astrana Health reported quarterly revenue of $486.30 million.
- Analysts had estimated revenue to be $440.68 million for the quarter.
- The company's revenue exceeded expectations by $45.62 million or approximately 10.3%.
3. **Surprise Estimates**:
- The company's EPS exceeded estimates by 1.9%.
- Revenue surpassed estimates by 10%.
4. **Stock Performance and Analyst Ratings**:
- Despite the positive earnings beat, ASTH's stock experienced a 2.4% decline and traded at $46.74 on the day of earnings release.
- The stock has an average analyst rating of "Buy" with a consensus price target of $55.75, indicating potential confidence in the company's future performance.

In conclusion, while ASTH's Q3 2024 earnings and revenue figures were slightly better than analyst forecasts, the stock's performance on the day of earnings release suggests that the market may have had concerns or reacted to other factors.